Aeglea BioTherapeutics Inc (AGLE)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Aeglea BioTherapeutics Inc (AGLE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014305
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aeglea BioTherapeutics Inc (Aeglea BioTherapeutics), formerly Aeglea BioTherapeutics Holdings, LLC is a biotechnology company that develops and commercializes engineered human enzymes for the treatment of cancer and rare genetic diseases. The company’s product pipeline comprises AEB1102, AEB3103, AEB2109, and AEB4104. It develops engineered human enzymes to target and degrade amino acids in the blood. Aeglea BioTherapeutics is developing products for the treatment of Arginase I Deficiency; homocystinuria and others. The company works in partnership with research institutions, allied healthcare providers and pharmaceutical companies to discover, develop and market new product candidates. Aeglea BioTherapeutics is headquartered in Austin, Texas, the US.

Aeglea BioTherapeutics Inc (AGLE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Aeglea Biotherapeutics Acquires In-Process R&D Assets from GMA Technologies 11
Venture Financing 12
Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 12
Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 14
Aeglea BioTherapeutics Raises US$5.1 Million In Venture Financing 15
Partnerships 16
Aeglea BioTherapeutics Enters into Agreement with Merck 16
Licensing Agreements 17
AEMase Enters into Licensing Agreement with University of Texas at Austin 17
AECase Enters into Licensing Agreement with University of Texas at Austin 18
Equity Offering 19
Aeglea BioTherapeutics Prices Public Offering of Shares for USD12.3 Million 19
Aeglea BioTherapeutics Raises USD54.8 million in IPO 20
Aeglea BioTherapeutics Inc – Key Competitors 21
Aeglea BioTherapeutics Inc – Key Employees 22
Aeglea BioTherapeutics Inc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Nov 07, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results 24
Aug 09, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial Results 25
May 09, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2017 Financial Results 26
Mar 23, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results 27
Nov 09, 2016: Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2016 Financial Results 29
Aug 09, 2016: Aeglea BioTherapeutics Announces Second Quarter 2016 Financial Results 31
May 19, 2016: Aeglea BioTherapeutics Announces First Quarter 2016 Financial Results 33
Corporate Communications 34
Jul 20, 2017: Aeglea BioTherapeutics Announces Leadership Change 34
Jul 10, 2017: Aeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer 35
Feb 16, 2017: Aeglea BioTherapeutics Appoints Dr. Suzanne Bruhn to Board of Directors 36
May 16, 2016: Aeglea BioTherapeutics Names Dr. Sandra Rojas-Caro as Chief Medical Officer 37
Mar 15, 2016: Aeglea BioTherapeutics Appoints Dr. Anthony Quinn to Board of Directors 38
Product News 39
11/08/2016: Aeglea BioTherapeutics to Present a Poster at the Society for Immunotherapy of Cancer 2016 Annual Meeting Suggesting Potential for AEB1102 Combination Therapy with Immuno-Oncology Checkpoint Inhibitors 39
Product Approvals 40
May 23, 2016: Aeglea BioTherapeutics Receives FDA Fast Track Designation for AEB1102 for the Treatment of Patients with Hyperargininemia Secondary to Arginase I Deficiency 40
Mar 14, 2016: Aeglea BioTherapeutics Announces FDA Acceptance of its Investigational New Drug Application for AEB1102 for the Treatment of Hematological Malignancies 41
Jan 07, 2016: Aeglea BioTherapeutics Announces FDA Acceptance of Its Investigational New Drug Application for AEB1102 for the Treatment of Arginase I Deficiency 42
Clinical Trials 43
Sep 15, 2016: Aeglea BioTherapeutics Doses First Patients in Phase 1 Trial of AEB1102 for the Treatment of Arginase I Deficiency 43
Aug 29, 2016: Aeglea BioTherapeutics Doses First Patient in Phase 1 Trial of AEB1102 for the Treatment of Hematological Malignancies 44
Jul 18, 2016: Aeglea BioTherapeutics Provides Update on AEB1102 Clinical Program in Rare Diseases and Cancer 45
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aeglea BioTherapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Aeglea Biotherapeutics Acquires In-Process R&D Assets from GMA Technologies 11
Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 12
Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 14
Aeglea BioTherapeutics Raises US$5.1 Million In Venture Financing 15
Aeglea BioTherapeutics Enters into Agreement with Merck 16
AEMase Enters into Licensing Agreement with University of Texas at Austin 17
AECase Enters into Licensing Agreement with University of Texas at Austin 18
Aeglea BioTherapeutics Prices Public Offering of Shares for USD12.3 Million 19
Aeglea BioTherapeutics Raises USD54.8 million in IPO 20
Aeglea BioTherapeutics Inc, Key Competitors 21
Aeglea BioTherapeutics Inc, Key Employees 22
Aeglea BioTherapeutics Inc, Subsidiaries 23

★海外企業調査レポート[Aeglea BioTherapeutics Inc (AGLE)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Adacel Technologies Limited:企業の戦略・SWOT・財務情報
    Adacel Technologies Limited - Strategy, SWOT and Corporate Finance Report Summary Adacel Technologies Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Insmed Inc (INSM)-医療機器分野:企業M&A・提携分析
    Summary Insmed Inc (Insmed) is a biopharmaceutical company that focuses on rare diseases. Its lead product candidate, Arikayce (liposomal amikacin for inhalation), is indicated for the treatment of nontuberculous mycobacteria (NTM) lung disease in adult patients. Its other clinical pipeline includes …
  • Galaxy Entertainment Group Ltd:企業の戦略・SWOT・財務情報
    Galaxy Entertainment Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Galaxy Entertainment Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Hikal Ltd (HIKAL):企業の財務・戦略的SWOT分析
    Summary Hikal Ltd (Hikal) is a pharmaceutical company that provides custom manufacturing; active ingredients and intermediates. The company provides product portfolio such as antiepileptic, antihistamine, antipsychotic and antilipemic, among others. It offers services such as custom synthesis, contr …
  • PHX Energy Services Corp (PHX):石油・ガス:M&Aディール及び事業提携情報
    Summary PHX Energy Services Corp (PHX Energy), formerly Phoenix Technology Income Fund is an energy service company that manufactures, designs, and engineers directional drilling technologies. The corporation’s equipment includes RADD, P-360 MWD, 360-CV MWD, E-360 MWD, 360 RWD, and performance motor …
  • Colgate-Palmolive Company:戦略・SWOT・企業財務分析
    Colgate-Palmolive Company - Strategy, SWOT and Corporate Finance Report Summary Colgate-Palmolive Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • One Lambda Inc:医療機器:M&Aディール及び事業提携情報
    Summary One Lambda Inc (One Lambda), a subsidiary of Thermo Fisher Scientific Inc is a medical device manufacturing company that offers laboratory products. The company develops and distributes antibody detection products and histocompatibility typing tests. Its products include HLA testing reagents …
  • Manchester United Plc:企業の戦略・SWOT・財務分析
    Manchester United Plc - Strategy, SWOT and Corporate Finance Report Summary Manchester United Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Hunan Corun New Energy Co Ltd (600478)-エネルギー分野:企業M&A・提携分析
    Summary Hunan Corun New Energy Co Ltd (Corun) is a battery manufacturing company that designs, research's, produces and commercializes materials and batteries. The company develops high quality energy materials, extension products and advanced batteries. It also manufactures ultra-intense bonding ni …
  • Abcam Plc (ABC):医療機器:M&Aディール及び事業提携情報
    Summary Abcam Plc (Abcam) is a supplier of life science research tools for analysis of living cells at molecular level to understand a wide range of disease conditions. The company develops and markets antibodies and other related products. Its product portfolio includes primary antibodies, secondar …
  • Washington University in St Louis:医療機器:M&Aディール及び事業提携情報
    Summary Washington University in St Louis (WUSTL), a subsidiary of University of Washington is an educational university which provides education and research services. The university provides various courses of bachelor’s, master’s, and doctoral degrees in a wide range of traditional and interdisci …
  • Hycrete Inc:企業の戦略的SWOT分析
    Hycrete Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • LG International Corp (001120):石油・ガス:M&Aディール及び事業提携情報
    Summary LG International Corp (LGI) is a diversified enterprise with business interests in various sectors including resources, infrastructure and industrial, and logistics. The company’s resources business is involved in coal, oil and gas, metals, food and commodities areas, while infrastructure an …
  • Procter & Gamble SA Pty Ltd:企業の戦略的SWOT分析
    Procter & Gamble SA Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • ITC Holdings Corp.:企業の発電所・SWOT分析2018
    ITC Holdings Corp. - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • ProAxsis Ltd:製品パイプライン分析
    Summary ProAxsis Ltd (ProAxsis), formerly ProAx-Sis Ltd, a subsidiary of NetScientific UK Ltd, is a developer of novel, point of care tests for the monitoring of patients with chronic diseases. The company develops proteasetags based point of care tests to offer a visual readout of active proteases …
  • Pan Orient Energy Corp (POE):石油・ガス:M&Aディール及び事業提携情報
    Summary Pan Orient Energy Corp (POE) is an independent upstream oil and gas company. The company has interests in onshore oil and gas assets in Thailand and Indonesia. It also has interests in Andora Energy Corporation, which holds properties in Northern Alberta. Its assets in Thailand include Conce …
  • Tufts Medical Center:製薬・医療:M&Aディール及び事業提携情報
    Summary Tufts Medical Center (TMC), formerly New England Medical Center Hospital Inc, a subsidiary of Tufts University School of Medicine, is an academic medical center that provides patient care services. The center offers treatments for brain tumor, breast cancer, cardiac arrhythmia, cardiomyopath …
  • Ability Pharmaceuticals SL-製薬・医療分野:企業M&A・提携分析
    Summary Ability Pharmaceuticals SL (Ability Pharma), formerly known as AB Therapeutics S.L., is a clinical stage biopharmaceutical company that focuses on drug discovery and development. It develops human therapeutics to treat lung, pancreatic and gynecological cancers. The company’s lead pipeline p …
  • Resona Holdings, Inc.:企業の戦略・SWOT・財務情報
    Resona Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Resona Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆